Objective To examine and evaluate current literature on the united states Food and Medication Administration (FDA)-approved medication enzalutamide (XTANDI?) in metastatic castration-resistant prostate cancers. docetaxel, following a Stage III trial (AFFIRM) that demonstrated a 4.8-month survival benefit within this population. Lately, the Daptomycin FDA extended the acceptance of enzalutamide as first-line therapy for metastatic castration-resistant… Continue reading Objective To examine and evaluate current literature on the united states